Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Innate Pharma (IPHA) Return on Sales (2023 - 2024)

Historic Return on Sales for Innate Pharma (IPHA) over the last 6 years, with Q2 2025 value amounting to 0.77%.

  • Innate Pharma's Return on Sales fell 7200.0% to 0.77% in Q2 2025 from the same period last year, while for Jun 2025 it was 0.77%, marking a year-over-year decrease of 7200.0%. This contributed to the annual value of 0.0% for FY2022, which is 2900.0% up from last year.
  • Innate Pharma's Return on Sales amounted to 0.77% in Q2 2025, which was down 7200.0% from 5.97% recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Return on Sales ranged from a high of 0.0% in Q4 2022 and a low of 5.97% during Q4 2024
  • For the 5-year period, Innate Pharma's Return on Sales averaged around 1.44%, with its median value being 0.53% (2021).
  • Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 37500bps in 2022, then tumbled by -58200bps in 2024.
  • Innate Pharma's Return on Sales (Quarter) stood at 3.75% in 2021, then surged by 100bps to 0.0% in 2022, then crashed by -12374bps to 0.15% in 2023, then tumbled by -3990bps to 5.97% in 2024, then surged by 87bps to 0.77% in 2025.
  • Its Return on Sales was 0.77% in Q2 2025, compared to 5.97% in Q4 2024 and 0.05% in Q2 2024.